🇺🇸 FDA
Pipeline program

Triple antithrombotic therapy

007

Approved small_molecule active

Quick answer

Triple antithrombotic therapy for Acute Coronary Syndrome (ACS) is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Acute Coronary Syndrome (ACS)
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials